Mekostest 36

Bacitracin, the active ingredient in Mekostest 36, is a dermatological antimicrobial presented as a topical formulation for skin use. It is employed to treat bacterial skin infections and inflammatory dermatoses in both adults and children. The combination formulation also includes anti‑inflammatory corticosteroids and antiseptic agents that broaden its therapeutic scope.

GNH USA supplies Mekostest 36 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and global markets.

Mekostest 36 is a topical combination used in dermatology to manage bacterial, inflammatory and fungal skin conditions.

- Impetigo: reduces bacterial colonisation and promotes lesion healing. - Atopic dermatitis flare: decreases inflammation, redness and itching. - Contact dermatitis: alleviates inflammatory response and prevents secondary infection. - Superficial fungal infection: provides antifungal activity to clear mild dermatophyte lesions. - Seborrheic dermatitis: controls microbial overgrowth and reduces scaling. - Minor burns: soothes irritation and helps prevent infection.

Mekostest 36 may cause local skin reactions and, rarely, systemic effects.

Common Side Effects: - Skin irritation or burning sensation. - Pruritus or mild itching. - Erythema or redness at the application site. - Dryness or peeling of the skin. - Contact dermatitis. - Mild stinging.

Serious or Rare Side Effects: - Allergic reaction with swelling, hives or angioedema. - Secondary infection due to over‑growth of resistant organisms. - Systemic corticosteroid effects such as adrenal suppression when used over large areas. - Severe skin necrosis or ulceration. - Anaphylaxis (rare).

When using Mekostest 36, follow these safety measures.

- Avoid application on extensive broken skin: limit use to small affected areas. - Do not use on the face or mucous membranes unless directed by a clinician. - Limit duration of therapy: typically no longer than 2 weeks without medical review. - Monitor for signs of infection or allergic reaction and discontinue if they occur. - Contraindicated in patients with known hypersensitivity to any component. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mekostest 36 can interact with other medications applied to the skin or taken systemically.

Major Interactions (Avoid): - Concurrent use of systemic corticosteroids: may increase risk of systemic steroid effects. - Other topical antibiotics: can promote resistant bacterial strains. - Immunosuppressive agents: heightened risk of opportunistic skin infections.

Moderate Interactions (Monitor Closely): - Occlusive dressings: may enhance percutaneous absorption of corticosteroids. - Topical antifungal agents: assess for additive irritation. - Wound‑healing products containing zinc or copper: may interfere with clioquinol activity.